Çağhan Kızıl (born October 14, 1981) is a Turkish/German neuroscientist and geneticist, and Professor of Neurological Sciences at the Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at the Columbia University Vagelos College of Physicians and Surgeons Columbia University Irving Medical Center."Announcement for Visiting Position and Award", LinkedIn, April 23, 2021"Department of Neurology Faculty Profile", Columbia University, November 23, 2022
His research culminates interdisciplinary approaches harboring genetics, neuroscience, cell biology, neuroimmunology, biotechnology and drug development. His team focuses on learning from Zebrafish how to enable the adult brain to better cope with neurodegenerative diseases and regenerate. By generating the first adult zebrafish brain Alzheimer's model,"Advances in Alzheimer's research by Dr. Çağhan Kızıl and his research group, TU Dresden press release", TU Dresden, April 22, 2019 and single cell sequencing-based investigation of the stem cell plasticity in this model,"How fish brain cells react to Alzheimer's disease, DZNE press release", German Center for Neurodegenerative Diseases (DZNE), Helmholtz Association, April 23, 2019 he aims to understand the molecular programs for zebrafish brain to induce regenerative neural stem cell plasticity and to investigate the functions of human genes related to Alzheimer's disease in zebrafish brain."Missing Link Between Alzheimer's and Vascular Disease Found?", Columbia University Irving Medical Center Newsroom, May 24, 2022 He develops tools for comparative studies in mammalian brains such as 3D human brain models as novel in vitro platforms for drug development."Alzheimer's in mini format", DZNE Press release, April 22, 2019
In 2024, Kizil and colleagues identified a rare protective variant in the fibronectin 1 (FN1) gene that was associated with a substantially reduced risk of Alzheimer's disease among carriers of the high-risk APOE ε4 allele. The study combined large-scale human genetic analyses with postmortem brain tissue and experimental validation in zebrafish, implicating fibronectin at the blood–brain barrier as a key mediator of Alzheimer's disease risk and a potential therapeutic target. The findings received broad coverage in the scientific and popular press, including by Alzforum, which described the work as identifying a rare protective variant that may explain resilience to APOE ε4-associated Alzheimer's disease, and Newsweek, which highlighted its implications for new therapeutic strategies. Building on this work, his laboratory subsequently showed that fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer's disease, disrupting astrocyte–endothelial interactions, in a study published in Nature Aging.
Previously, he was leading Helmholtz research group in German Center for Neurodegenerative Diseases within Helmholtz Association."Çağhan Kızıl's website - DZNE", DZNE, April 22, 2019"Kizil Lab's website – Kizil Lab", Kizil Lab, April 22, 2019 He established his lab after receiving Helmholtz Young investigator award in 2013."1.7 million Euros for young Dresden based researcher", DZNE Press release, April 22, 2019"New Helmholtz young investigators", Helmholtz Association, April 22, 2019"Zebra Balığı Alzheimer'dan Çıkış Yolumuz mu? | Çağhan KIZIL | TEDxAnkara", TEDx Ankara, February 20, 2019 In 2014, he became Docent (Associate Professor) by Council of Higher Education (Turkey). In 2019, he became a tenured group leader in DZNE Dresden within the Helmholtz Association. He was the founder CEO of the first spin-off company of German Center for Neurodegenerative Diseases, Neuron-D GmbH "DZNE's First Spin-off “Neuron–D” Uses Innovative Technology for Drug Testing", DZNE Press release, March 18, 2021 that specializes on 3D high-throughput drug screening platform for neurological diseases."NEURON-D by DZNE, Video", DZNE introduction video, March 18, 2021
References
External links